Biosimilars and generics are growing at 8.78% CAGR through 2031, steadily eroding innovators share and lowering therapy costs
Alternatively, you can purchase ready-to-administer formulations from FDA-registered 503B outsourcing facilities, which handle the compounding and provide tested, labeled products
Ray KK, Seshasai SRK, Wijesuriya S et al
Head-to-head trial data (SURMOUNT-5, 2025) showed tirzepatide produced 20.2 percent mean weight loss versus semaglutide's 13.7 percent at equivalent therapeutic doses over 72 weeks
Studies in animals show GLP1 activation can reduce seeking of things like sugary food, alcohol, nicotine, and even cocaine
Ozempic, in this context, falls within a similar therapeutic area